2021 ESC/EACTS Guidelines for the management of valvular heart disease: developed by the Task Force for the management of valvular heart disease of the …

A Vahanian, F Beyersdorf, F Praz… - European heart …, 2022 - academic.oup.com
Health professionals are encouraged to take the ESC/EACTS Guidelines fully into account
when exercising their clinical judgment, as well as in the determination and the …

Management of patients at risk for and with left ventricular thrombus: a scientific statement from the American Heart Association

GN Levine, JW McEvoy, JC Fang, C Ibeh… - Circulation, 2022 - Am Heart Assoc
Despite the many advances in cardiovascular medicine, decisions concerning the
diagnosis, prevention, and treatment of left ventricular (LV) thrombus often remain …

Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a …

P Vranckx, M Valgimigli, L Eckardt, J Tijssen… - The Lancet, 2019 - thelancet.com
Background We aimed to assess the safety of edoxaban in combination with P2Y12
inhibition in patients with atrial fibrillation who had percutaneous coronary intervention (PCI) …

2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of …

B Ibanez, S James, S Agewall, MJ Antunes… - European heart …, 2018 - academic.oup.com
Surveys and registries are needed to verify that real-life daily practice is in keeping with what
is recommended in the guidelines, thus completing the loop between clinical research …

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy …

M Valgimigli, H Bueno, RA Byrne, JP Collet… - European heart …, 2018 - academic.oup.com
Guidelines, Aspirin, Clopidogrel, Ticagrelor, Prasugrel, Dual antiplatelet therapy, Acute
coronary syndromes, Coronary artery bypass grafting, Coronary artery disease, Drug-eluting …

2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing …

DJ Kumbhani, CP Cannon, CJ Beavers… - Journal of the American …, 2021 - jacc.org
The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …

Direct oral anticoagulant use: a practical guide to common clinical challenges

A Chen, E Stecker, B A. Warden - Journal of the American Heart …, 2020 - Am Heart Assoc
Direct oral anticoagulants (DOAC s) have quickly become attractive alternatives to the long‐
standing standard of care in anticoagulation, vitamin K antagonist. DOAC s are indicated for …

[PDF][PDF] 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

P Kirchhof, S Benussi, D Kotecha… - Polish Heart …, 2016 - journals.viamedica.pl
Komisję ESC ds. Wytycznych Postępowania nadzoruje i koordynuje przygotowywanie
nowych wytycznych i stanowisk przez grupy robocze i inne grupy ekspertów. Komitet jest …

[HTML][HTML] Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation

VJ Nijenhuis, J Brouwer, R Delewi… - … England Journal of …, 2020 - Mass Medical Soc
Background The roles of anticoagulation alone or with an antiplatelet agent after
transcatheter aortic-valve implantation (TAVI) have not been well studied. Methods We …

2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of …

GN Levine, ER Bates, JA Bittl, RG Brindis, SD Fihn… - Circulation, 2016 - Am Heart Assoc
The scope of this focused update is limited to addressing recommendations on duration of
dual antiplatelet therapy (DAPT)(aspirin plus a P2Y12 inhibitor) in patients with coronary …